Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Operating Leases (2020 - 2025)

Historic Operating Leases for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $5.3 million.

  • Arcutis Biotherapeutics' Operating Leases rose 9033.19% to $5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year increase of 9033.19%. This contributed to the annual value of $2.6 million for FY2024, which is 2424.6% down from last year.
  • According to the latest figures from Q3 2025, Arcutis Biotherapeutics' Operating Leases is $5.3 million, which was up 9033.19% from $2.1 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Operating Leases' 5-year high stood at $5.3 million during Q3 2025, with a 5-year trough of $2.1 million in Q2 2025.
  • In the last 5 years, Arcutis Biotherapeutics' Operating Leases had a median value of $4.4 million in 2023 and averaged $4.1 million.
  • In the last 5 years, Arcutis Biotherapeutics' Operating Leases soared by 181287.88% in 2021 and then tumbled by 3530.92% in 2024.
  • Arcutis Biotherapeutics' Operating Leases (Quarter) stood at $4.8 million in 2021, then dropped by 13.76% to $4.1 million in 2022, then dropped by 17.85% to $3.4 million in 2023, then dropped by 24.25% to $2.6 million in 2024, then surged by 105.93% to $5.3 million in 2025.
  • Its Operating Leases stands at $5.3 million for Q3 2025, versus $2.1 million for Q2 2025 and $2.3 million for Q1 2025.